JP2025032110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025032110A5 JP2025032110A5 JP2024196799A JP2024196799A JP2025032110A5 JP 2025032110 A5 JP2025032110 A5 JP 2025032110A5 JP 2024196799 A JP2024196799 A JP 2024196799A JP 2024196799 A JP2024196799 A JP 2024196799A JP 2025032110 A5 JP2025032110 A5 JP 2025032110A5
- Authority
- JP
- Japan
- Prior art keywords
- aav
- seq
- protein
- capsid protein
- aav capsid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025085876A JP2025119015A (ja) | 2019-05-24 | 2025-05-22 | 改変ウイルス粒子およびその使用 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852791P | 2019-05-24 | 2019-05-24 | |
| US62/852,791 | 2019-05-24 | ||
| PCT/US2020/034328 WO2020242984A1 (en) | 2019-05-24 | 2020-05-22 | Modified viral particles and uses thereof |
| JP2021569402A JP2022533438A (ja) | 2019-05-24 | 2020-05-22 | 改変ウイルス粒子およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569402A Division JP2022533438A (ja) | 2019-05-24 | 2020-05-22 | 改変ウイルス粒子およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085876A Division JP2025119015A (ja) | 2019-05-24 | 2025-05-22 | 改変ウイルス粒子およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025032110A JP2025032110A (ja) | 2025-03-11 |
| JP2025032110A5 true JP2025032110A5 (enExample) | 2025-06-02 |
Family
ID=71094822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569402A Pending JP2022533438A (ja) | 2019-05-24 | 2020-05-22 | 改変ウイルス粒子およびその使用 |
| JP2024196799A Pending JP2025032110A (ja) | 2019-05-24 | 2024-11-11 | 改変ウイルス粒子およびその使用 |
| JP2025085876A Pending JP2025119015A (ja) | 2019-05-24 | 2025-05-22 | 改変ウイルス粒子およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569402A Pending JP2022533438A (ja) | 2019-05-24 | 2020-05-22 | 改変ウイルス粒子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025085876A Pending JP2025119015A (ja) | 2019-05-24 | 2025-05-22 | 改変ウイルス粒子およびその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220241430A1 (enExample) |
| EP (1) | EP3976631A1 (enExample) |
| JP (3) | JP2022533438A (enExample) |
| KR (1) | KR20220011664A (enExample) |
| CN (2) | CN113874386A (enExample) |
| AR (2) | AR118997A1 (enExample) |
| AU (1) | AU2020283537A1 (enExample) |
| BR (1) | BR112021023692A2 (enExample) |
| CA (1) | CA3140386A1 (enExample) |
| CL (2) | CL2021003096A1 (enExample) |
| CO (1) | CO2021017692A2 (enExample) |
| IL (1) | IL288233A (enExample) |
| MA (1) | MA56035A (enExample) |
| MX (1) | MX2021014338A (enExample) |
| PE (1) | PE20212357A1 (enExample) |
| PH (1) | PH12021552887A1 (enExample) |
| SG (1) | SG11202112917PA (enExample) |
| TW (1) | TW202110869A (enExample) |
| WO (1) | WO2020242984A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12421525B2 (en) | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| AU2020283537A1 (en) * | 2019-05-24 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
| US20240124892A1 (en) * | 2021-03-02 | 2024-04-18 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Adeno-associated viruses and methods and materials for making and using adeno-associated viruses |
| US20250195693A1 (en) * | 2021-04-30 | 2025-06-19 | Duke University | Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same |
| EP4359550A1 (en) * | 2021-06-23 | 2024-05-01 | Dyno Therapeutics, Inc. | Capsid variants and methods of using the same |
| AU2023269134A1 (en) | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| EP4766849A2 (en) * | 2023-08-24 | 2026-07-01 | Ohio State Innovation Foundation | Dosages and quality control methods for genome encapsidation for gene therapy purposes |
| CN121794393A (zh) * | 2023-09-07 | 2026-04-03 | 里珍纳龙药品有限公司 | 经共价表面修饰的腺相关病毒的生产和纯化 |
| WO2025111473A1 (en) * | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
| WO2026112457A2 (en) * | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261554B1 (en) * | 1995-07-25 | 2001-07-17 | Introgene B.V. | Compositions for targeted gene delivery |
| AU4645697A (en) | 1996-09-11 | 1998-04-02 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Aav4 vector and uses thereof |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| DE69936104T2 (de) | 1998-11-05 | 2008-01-17 | The Trustees Of The University Of Pennsylvania | Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten |
| CN103589692B (zh) * | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| EP2158211B1 (en) | 2007-05-31 | 2016-08-10 | Medigene AG | Mutated structural protein of a parvovirus |
| WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
| ES2926774T3 (es) * | 2013-03-15 | 2022-10-28 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores AAV de doble unión de glicano |
| WO2015137802A1 (en) * | 2014-03-10 | 2015-09-17 | Uniqure Ip B.V. | Further improved aav vectors produced in insect cells |
| AU2015230938C1 (en) | 2014-03-21 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10550405B2 (en) * | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| EP4706687A3 (en) | 2017-06-27 | 2026-07-15 | Regeneron Pharmaceuticals, Inc. | Tropism-modified recombinant viral particles and uses thereof for the targeted introduction of genetic material into human cells |
| SI3645551T1 (sl) | 2017-06-27 | 2024-06-28 | Regeneron Pharmaceuticals, Inc. | S tropizmi spremenjeni rekombinantni virusni vektorji in njihova uporaba za tarčni vnos genetskega materiala v človeške celice |
| US12421525B2 (en) * | 2018-02-28 | 2025-09-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Conjugates comprising AAVs and CAS9 polypeptides |
| AU2020283537A1 (en) * | 2019-05-24 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
-
2020
- 2020-05-22 AU AU2020283537A patent/AU2020283537A1/en active Pending
- 2020-05-22 PE PE2021001934A patent/PE20212357A1/es unknown
- 2020-05-22 SG SG11202112917PA patent/SG11202112917PA/en unknown
- 2020-05-22 CN CN202080038612.3A patent/CN113874386A/zh active Pending
- 2020-05-22 CA CA3140386A patent/CA3140386A1/en active Pending
- 2020-05-22 BR BR112021023692A patent/BR112021023692A2/pt unknown
- 2020-05-22 PH PH1/2021/552887A patent/PH12021552887A1/en unknown
- 2020-05-22 JP JP2021569402A patent/JP2022533438A/ja active Pending
- 2020-05-22 TW TW109117155A patent/TW202110869A/zh unknown
- 2020-05-22 EP EP20733099.4A patent/EP3976631A1/en active Pending
- 2020-05-22 KR KR1020217041074A patent/KR20220011664A/ko active Pending
- 2020-05-22 MA MA056035A patent/MA56035A/fr unknown
- 2020-05-22 CN CN202210622571.3A patent/CN114989267A/zh active Pending
- 2020-05-22 US US17/612,669 patent/US20220241430A1/en active Pending
- 2020-05-22 AR ARP200101465A patent/AR118997A1/es unknown
- 2020-05-22 WO PCT/US2020/034328 patent/WO2020242984A1/en not_active Ceased
- 2020-05-22 MX MX2021014338A patent/MX2021014338A/es unknown
-
2021
- 2021-11-18 IL IL288233A patent/IL288233A/en unknown
- 2021-11-19 AR ARP210103220A patent/AR124119A2/es unknown
- 2021-11-23 CL CL2021003096A patent/CL2021003096A1/es unknown
- 2021-12-22 CO CONC2021/0017692A patent/CO2021017692A2/es unknown
-
2023
- 2023-03-03 CL CL2023000629A patent/CL2023000629A1/es unknown
-
2024
- 2024-11-11 JP JP2024196799A patent/JP2025032110A/ja active Pending
-
2025
- 2025-05-22 JP JP2025085876A patent/JP2025119015A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ikeda et al. | Ligand-targeted delivery of therapeutic siRNA | |
| US9951329B2 (en) | Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles | |
| FI3645553T3 (fi) | Tropismilla muokattuja rekombinantteja viruspartikkeleita ja niiden käyttöjä geneettisen materiaalin viemiseksi kohdennetusti ihmissoluihin | |
| US9302014B2 (en) | Cell-penetrating peptides having a central hydrophobic domain | |
| JP2022530633A5 (enExample) | ||
| CN103313730B (zh) | 用于治疗癌症的肽靶向系统的组合物 | |
| JP2022530656A5 (enExample) | ||
| JP2022530544A5 (enExample) | ||
| KR20240113624A (ko) | Aav 캡시드 변이체 및 이의 용도 | |
| FI4211231T3 (fi) | Peptidimodifioitu aav-kapsidi | |
| JP2023544683A5 (enExample) | ||
| JP2014504150A5 (enExample) | ||
| US20220282276A1 (en) | Chemically-modified adeno-associated virus | |
| JP2010533170A (ja) | 化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子 | |
| WO2012142659A1 (en) | Site-selective modification of proteins | |
| JP2022533438A5 (enExample) | ||
| AU2014267044A1 (en) | Bacteriophage | |
| CN114539422A (zh) | 核酸多聚化介导的多价蛋白药物和疫苗的构建方法及应用 | |
| JP2024543211A5 (enExample) | ||
| JP2023506635A (ja) | Ｎ－アセチルガラクトサミン結合ポリペプチドを含むｍＲＮＡ標的化分子およびその調製方法 | |
| JP2025514348A5 (enExample) | ||
| JP2025507359A5 (enExample) | ||
| JP7697656B2 (ja) | 人工ウイルスキャプシド | |
| Alleva et al. | Functionalizing Nucleic Acids: Synthesis and Purification Strategies for Bioconjugates as Biomaterials | |
| CN112166196A (zh) | 大核酸的靶向细胞内递送 |